
Global Capital Exodus From Life Science Tech Signals AI Investment Realignment
10x Genomics' accelerating financial deterioration is exposing a fault line running through life science technology markets worldwide, as institutional investors pivot decisively toward core AI infrastructure. The pattern — visible from Silicon Valley to Singapore — suggests a structural repricing of companies that use AI tools versus those that build AI's foundational architecture. For the genomics sector globally, the reckoning has only begun.


